Aslan Pharmaceuticals LT-ADRASLN
13F holders, Q3 2025 (September 30)1holders
0new positions
0sold out
$0.59avg. 13F price*
At the end of Q3 2025, 1 institutions reported holding Aslan Pharmaceuticals LT-ADR (ASLN) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holder was Rhumbline Advisers ($17).
- Company
- Aslan Pharmaceuticals LT-ADR
- CUSIP
- 04522R309
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 72 shares sold, net −72 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Rhumbline Advisers | 0.00% | Reduce -71.3% | 29 | $17 |
"% of holder's portfolio" is ASLN's weight in each manager's 13F, not the share of Aslan Pharmaceuticals LT-ADR the manager owns.